Thymosin Alpha-1

WHAT IT DOES

Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from thymus tissue as the fraction that restored immune function in thymectomized mice. Its proposed mechanism is not receptor agonism in the usual sense. It signals through Toll-like receptors on both myeloid and plasmacytoid dendritic cells, which activates downstream signaling and cytokine production and in turn shifts T cell activation, an effect described in a review by authors affiliated with the manufacturer (King 2016, PMID: 27450734). In mice it also induced the tolerogenic IDO1 pathway in the gut, which is the opposite of pure immune stimulation and points to a context-dependent regulator rather than a one-directional booster (Renga 2020, PMID: 32817121; mouse data only). The clinical read-through, where it exists, is on immune restoration markers in acutely immunosuppressed patients: monocyte HLA-DR in sepsis and CD4/CD8 ratio in severe acute pancreatitis, where a meta-analysis of 5 RCTs and 706 patients found CD4 percentage rose by 4.53 points and the CD4/CD8 ratio by 0.42 (Tian 2025, PMID: 40599771).

Route matters more here than for almost any ingredient Avelor covers. Pharmacokinetic work in healthy volunteers measured plasma and urine levels after a single subcutaneous injection (Wang 2019, PMID: 30903925). A 28-amino-acid peptide swallowed in a capsule is digested by gastric and pancreatic proteases before absorption. Avelor located no human data showing that any oral, sublingual, or transdermal thymosin alpha-1 product reaches systemic circulation intact.

SAFETY PROFILE

Avelor located no dedicated drug-drug interaction studies for thymosin alpha-1. The tables below are built from co-administration patterns observed in the retrieved trials and from mechanism. Treat all of it as low-certainty.

Critical Interactions (Do Not Combine Without Medical Supervision)

Moderate Interactions (Monitor Closely)

Theoretical/Low-Risk Interactions